ClinicalTrials.gg
CompletedNCT04940741Updated Apr 8, 2024

Efficacy and Safety of VER-01 in the Treatment of Patients With Chronic Non-specific Low Back Pain

A Phase 3 interventional study of VER-01 and Placebo in Chronic Non-specific Low Back Pain, sponsored by Vertanical GmbH. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-08.

Sponsored by Vertanical GmbH · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
820
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies in Low Back Pain with a site in Germany — 5 open to participants now, 8 under way, 3 of them phase 3. Low Back Pain · Germany.

Enrollment
2nd of 54
820 · median 128
Started
2021
with 3 others
Phase 3
14 of 59
2 open now
Registered
43rd of 59
by date
Lead sponsor
2 of 59
Vertanical GmbH

Among the 59 studies in Low Back Pain with a site in Germany, this one is the 2nd largest by enrollment of the 54 interventional ones that give a count, is one of 4 that started in 2021, is one of 14 in phase 3, and was the 43rd registered.

Low Back Pain

2,926 studies on the registry are indexed under Low Back Pain; 579 are open to participants now.

Browse Low Back Pain studies →

Open to participants now

5 of the 59 studies in Low Back Pain with a site in Germany are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Low Back Pain with a site in Germany, or all of them as a file.
02

Study summary

Analysis of the efficacy, maintenance of efficacy, long-term safety, and investigation of the potential for dependence and abuse and the effect of abrupt drug withdrawal of VER-01 in the treatment of patients with chronic non-specific low back pain when drug treatment is indicated and previous optimised treatments with non-opioid analgesics have not led to sufficient pain relief or were unsuitable due to contraindications or intolerance.

Read the detailed description

The study is divided into four phases: Phase A, B, C and D. All patients who have completed Phase A and for whom the investigator considers further participation to be safe shall begin Phase B. Phases C and D run in parallel, so that patients who have completed Phase B and for whom the investigator considers further participation to be safe can be assigned to one of the two phases.

Phases A and D follow a double-blind, placebo-controlled design, while Phase B and C have an open-label design.

The main goal of Phase A is to demonstrate the efficacy of VER-01 compared to placebo. In Phase B and C the main goal is the investigation of long-term safety of VER-01. In Phase D the primary objective is to demonstrate the maintenance of efficacy of VER-01 on a placebo-controlled basis.

The potential for dependence and abuse will be analyzed in all Phases (A,B,C,D), while the effect of abrupt drug withdrawal of VER-01 will be analyzed in Phase C and D.

03

Conditions studied

  • Chronic Non-specific Low Back Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female patients (18 years and older)
  2. Chronic (for at least three months) non-specific pain in the lower back (between the lower ribcage and the gluteal folds)
  3. Pain intensity on average at least 4 points on an 11-point NRS (one month before the start of the study)
  4. Patients with indicated drug treatment where previous optimised treatments with non-opioid analgesics have not led to sufficient pain relief or were unsuitable due to or intolerance.
  5. Willingness of both men and women to use a reliable method of during study participation and for three months after taking the last dose of the IMP
  6. Signed patient information and form is available
  7. Understanding of the German language, ability to give consent and compliance
  8. The patient has understood the instructions to avoid changes in lifestyle and dietary habits
  9. The patient has understood the principle of the patient diary and gives their consent to keep it as instructed

Additional for Phase A

a1. Pain intensity averaged at least 4 points on an 11-point NRS (there must be at least 5 pain intensity readings in the morning from the run-in phase)

a2. Willingness not to take any analgesic medication (non-opioid and opioid analgesics as well as adjuvant analgesics) during participation in study Phase A (except rescue medication)

a3. Willingness to continue a current non-drug therapy unchanged as planned during participation in Phase A

Additional for Phase B

b1. Previous and complete participation in Phase A until and including Visit A6

b2. Patient wishes to participate voluntarily in the long-term study

b3. From the investigator's point of view, further participation is considered medically safe

b4. Willingness not to take any additional analgesic medication (non-opioid and opioid analgesics as well as adjuvant analgesics) during the last three weeks of study Phase B (except rescue medication).

Additional for Phase C

c1. Previous and complete participation in Phase B until and including Visit B10

c2. Patient wishes to participate voluntarily in the long-term study

c3. From the investigator's point of view, further participation is considered medically safe

Additional for Phase D

d1. Previous and complete participation in Phase B until and including Visit B10 (patients received Ver-01 for 26 weeks)

d2. Patient has experienced a pain score improvement of at least 30% in treatment Phase B (mean value of the study week 43 compared to the mean value of the run-in phase, there must be at least four values from study week 43 and five values from the run-in phase)

d3. Patient wishes to participate voluntarily in the study

d4. From the investigator's point of view, further participation is considered medically safe

d5. Willingness not to take any analgesic medication (non-opioid and opioid analgesics as well as adjuvant analgesics) during participation in study Phase D (except rescue medication)

d6. Willingness to continue a current non-drug therapy unchanged as planned during study

Exclusion criteria

Exclusion Criteria:

  1. Professional groups for which the ability to operate machinery and drive vehicles is the primary activity (including truck, bus and forklift drivers, pilots)
  2. Alcohol/drug/medication abuse and previous or current intake of methadone in the patient's medical history or suspected by the investigator
  3. Intake of analgesic medication (non-opioid and opioid analgesics as well as adjuvant analgesics) within seven days prior to the start of the study
  4. Taking cannabis-based products within 30 days prior to the start of the study
  5. , dementia (which impairs the assessment of symptoms)
  6. Severe forms of the following diseases: Anaemia,hematological//endocrinal/ renal/hepatic/respiratory/cardiovascular or gastrointestinal diseases, symptomatic peripheral vascular diseases
  7. Cardiovascular event in the past three months, poorly managed high blood pressure, untreated hypothyroidism, patients with Crigler-Najjar syndrome or Rotor syndrome, surgery within the past two months
  8. Severe mental illnesses (e.g. psychosis, schizophrenia, bipolar disorder), severe depression that is not due to the chronic non-specific low back pain, or individuals at risk of suicide (examined using the MINI questionnaire)
  9. Severe mental illness (psychosis, schizophrenia, bipolar disorder, severe depression, anxiety disorder) in a first-degree relative (parents and children); suicide in a first-degree relative (parents and children)
  10. Patients with an active cancer or tumor-related pain or severe pain due to physical injury
  11. Other painful comorbidities, excluding low back pain, that could interfere with the patient's evaluation during the study or the assessment of pain
  12. Well-known strong adverse events in connection with cannabis consumption before the start of the study
  13. Known allergy to cannabis and/or sesame seeds and products derived from them
  14. Known to the ingredients of the rescue medication
  15. Planned blood donation, planned sperm or egg donation, planned freezing of eggs or sperm
  16. Pregnancy, breastfeeding, desire to have children (within the next 20 months)
  17. Participation in another clinical trial within the past 30 days before the start of the study
  18. Inability to give consent, care dependency, patient has a legal guardian/caregiver, or is immobile
  19. The patient is in need of special protection (e.g., incarcerated; institutionalized by a court or judicial authority; in a dependent or employment relationship with the sponsor, an external service provider of the sponsor (who is involved in the study conduct), the investigator, or the study site).

Additional for Phase A:

a1. In the case of a current non-drug therapy (e.g. physical or behavioural therapy, acupuncture,massage, thermotherapy), which significantly modulates the perception of pain, it was not maintained unchanged for at least eight weeks prior to study participation in Phase A.

Additional for Phase D

d1. Intake of additional analgesic medication (non-opioid and opioid analgesics as well as adjuvant analgesics) within 21 days prior to the start of study Phase D (except rescue medication).

d2. In the case of a current non-drug therapy (e.g. physical or behavioural therapy, acupuncture,massage, thermotherapy) that significantly modulates the perception of pain, it was not maintained unchanged for at least nine weeks prior to the start of study Phase D.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
820 participants (actual)

Study arms

  • Experimental
    VER-01

    VER-01 is administered orally (b.i.d.) using a dosing syringe. One unit corresponds to 2.5 mg THC. The optimal dose is titrated on a patient-by-patient basis. The maximum daily dose should not exceed 13 dose units (32.5 mg THC).

    Drug: VER-01

  • Placebo comparator
    Placebo

    The Placebo is administered orally (b.i.d.) using a dosing syringe. The optimal dose is titrated on a patient-by-patient basis, analogous to VER-01.

    Other: Placebo

Interventions

  • DrugVER-01

    standardised cannabis extract (containing 21 mg THC per gram drug product)

  • OtherPlacebo

    comparator without active ingredient

06

What researchers measure

Primary outcomes

  1. Phase A: Efficacy based on pain reduction

    Change in average pain intensity compared to baseline on an 11-point Numerical Rating Scale (NRS, where 0=no pain to 10=worst pain imaginable) (mean value of study week 15 compared to the mean value of the seven-day run-in phase with daily documentation of pain intensity in the morning).

    Time frame: Baseline up to 15 weeks

  2. Phase B: Safety based on occurrence of treatment-related AEs/SAEs

    Safety and adverse reactions based on occurrence of treatment-related AEs/SAEs

    Time frame: Up to 29 weeks

  3. Phase C: Safety based on occurrence of treatment-related AEs/SAEs

    Safety and adverse reactions based on occurrence of treatment-related AEs/SAEs

    Time frame: Up to 28 weeks

  4. Phase D: Maintenance of efficacy

    Time until treatment failure defined as the time in days from randomization to phase D (R2) until the first day of treatment failure. Treatment failure is assessed by the daily calculated seven-day mean value of the pain score (11 point Numerical Rating Scale, NRS, where 0=no pain to 10=worst pain imaginable) in the morning during the treatment period, which must have deteriorated by at least 20% and at least one point compared to baseline (mean value of study week 43). The first day of treatment failure is then the earliest day within this seven-day time window to which this criterion applies as a single day. Furthermore, treatment failure is defined as a premature discontinuation of treatment for selected reasons.

    Time frame: Up to 4 weeks (from date of randomization R2 until the first day of treatment failure)

Secondary outcomes

  1. Phase A, B, C, D: Mean change in neuropathic pain

    Absolute change compared to baseline (day1) Neuropathic Pain Symptom Inventory (NPSI) total score at the end of each treatment phase in patients with neuropathic pain

    Time frame: Day 1, day 106, day 309, day 351, day 505

  2. Phase A, B, C, D: Change in pain intensity in the morning, as well as in the morning and evening

    Absolute changes from baseline in mean pain intensity at the end of each treatment phase measured in the morning (primary endpoint of Phase A) or morning and evening on an 11-point Numerical Rating Scale (NRS, where 0=no pain to 10=worst pain imaginable)

    Time frame: Baseline up to 72 weeks

  3. Phases A, B, C and D: Pain responders (30 percent and 50 percent) in the morning, as well as in the morning and evening

    The number and proportion of 30 percent and 50 percent pain responders in the morning, and morning and evening at the end of each treatment phase.

    Time frame: Baseline up to 72 weeks

  4. Phases A, B, C and D: Sleep quality (NRS)

    The absolute change from baseline in mean sleep quality at the end of each treatment phase measured on an 11-point Numerical Rating Scale (NRS, where 0=not impacted to 10=completely impacted)

    Time frame: Baseline up to 72 weeks

  5. Phase A: Sleep quality (MOS-SS)

    Absolute changes from baseline of sleep quality measured by Medical Outcomes Study Sleep Scale (MOS-SS) per survey point

    Time frame: Day 1, Day 22, Day 50, Day 78, Day 106

  6. Phase A: Intake of rescue and concomitant medication

    Cumulative dose of rescue medication taken in Phase A

    Time frame: Up to 16 weeks

  7. Phase D: Intake of rescue and concomitant medication

    Cumulative dose of rescue medication taken in Phase D

    Time frame: Up to 6 weeks

  8. Phases A, B, C and D: Depression Anxiety Stress Scales (DASS)

    Scores and absolute changes from baseline of depression, anxiety and stress levels measured by the DASS (where 0=did not apply to me at all to 3=affected me very greatly or most of the time) per time point of assessment

    Time frame: Baseline up to 72 weeks

  9. Phases A, B, C and D: Global assessment of symptoms (patient global impression of change, PGIC)

    Percentage of patients by category of the global assessment of symptoms (PGIC, 7-point Likert scale where 0=very much better to 6=very much worse) by the patient per survey point

    Time frame: Day 106, day 309, day 491, day 337

  10. Phases A, B, C and D: Satisfaction with the treatment result - patient

    Percentage of patients by category of the satisfaction with the treatment outcome (5-point Likert scale, where 0=very satisfied to 4=very unsatisfied) by the patient per survey point

    Time frame: Day 106, day 309, day 491, day 337

  11. Phases A, B, C and D: Satisfaction with the treatment result - investigator

    Percentage of patients by category of satisfaction with the treatment outcome (5-point Likert scale, where 0=very satisfied to 4=very unsatisfied) by the investigator per survey point.

    Time frame: Day 106, day 309, day 491, day 337

  12. Phases A, B, C and D: Satisfaction with tolerability - patient

    Percentage of patients by category of satisfaction with the tolerability (5-point Likert scale, where 0=very satisfied to 4=very unsatisfied) by the patient per survey point

    Time frame: Day 106, day 309, day 491, day 337

  13. Phase A: Safety and adverse reactions

    Safety and adverse reactions based on occurrence of treatment-related AEs/SAEs

    Time frame: Up to 16 weeks

  14. Phase D: Safety and adverse reactions

    Safety and adverse reactions based on occurrence of treatment-related AEs/SAEs

    Time frame: Up to 6 weeks

  15. Phases A, B, C and D: Quality of life scores (Short Form 36, SF-36)

    Scores in quality of life measured per survey point

    Time frame: Day 1, day 22, day 50, day 78, day 106, day 309, day 491, day 337

  16. Phases A, B, C and D: Quality of life absolute changes (Short Form 36, SF-36)

    Absolute changes in quality of life from baseline (day 1) measured per survey point

    Time frame: Day 1, day 22, day 50, day 78, day 106, day 309, day 491, day 337

  17. Phase A: Scores in bodily function and impairment due to low back pain (Roland Morris Disability Questionnaire, RMD)

    Scores in bodily function and impairment due to low back pain assessed by the RMD per survey point

    Time frame: Day 1, day 22, day 106

  18. Phase A: Absolute changes in bodily function and impairment due to low back pain(Roland Morris Disability Questionnaire, RMD)

    Absolute changes in bodily function and impairment due to low back pain assessed by the RMD per survey point

    Time frame: Day 1, day 22, day 106

  19. Phases A, B, C and D: Addiction (Addiction Behaviors Checklist ,ABC)

    The absolute number of positive answers of the ABC

    Time frame: Day 22, day 50, day 78, day 106, day 127, day 183, day 239, day 309, day 365, day 421, day 491, day 337

  20. Phase C: Diagnosis of substance dependence ICD-10 (International Statistical Classification of Diseases and Related Health Problems)

    The absolute number of positive answers according to the German Bundesärztekammer (2007) is summarized descriptively according to the standard for continuous parameters.

    Time frame: Day 491

  21. Phase A, B, C and D: Adverse events (AEs)

    Occurrence of AEs/SAEs

    Time frame: Through study completion, up to 72 weeks

  22. Phase C: Withdrawal symptoms (Cannabis Withdrawal Scale, CWS)

    Sum scores for intensity and functional impairment are descriptively analysed according to Allsop et al.

    Time frame: Up to 2 weeks

  23. Phase D: Withdrawal symptoms (Cannabis Withdrawal Scale, CWS)

    Sum scores for intensity and functional impairment are descriptively analysed according to Allsop et al.

    Time frame: Up to 4 weeks

07

Study locations

1 site
  • Emovis GmbH
    Berlin, 10629, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Mar 2024, 32 months.

Of 35 phase 3 interventional studies under Low Back Pain, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 40. This study's 32 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2021
First posted
Jun 28, 2021
StartActual
Jul 7, 2021
Primary completionActual
Mar 26, 2024
CompletionActual
Mar 26, 2024
Last update
Apr 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04940741
Lead sponsor
Vertanical GmbH
Responsible party
Sponsor
First posted
Jun 28, 2021
Start date
Jul 7, 2021
Primary completion
Mar 26, 2024
Completion
Mar 26, 2024
Last update
Apr 8, 2024

Study contacts

Joachim Nadstawek, Prof.
principal investigator · Schmerzzentrum Bonn

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VER-01

Start the discussion